Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Recursion Pharmaceuticals, Inc. (RXRX : NSDQ)

• Company Description    Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY. Number of Employees: 600

• Price / Volume Information    Yesterday's Closing Price: $3.01 Daily Weekly Monthly 20 Day Moving Average: 13,518,968 shares Shares Outstanding: 529.91 (millions) Market Capitalization: $1,595.01 (millions) Beta: 1.05 52 Week High: $7.18 52 Week Low: $2.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.00% -18.20% 12 Week -20.16% -26.19% Year To Date -26.41% -30.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 41S RIO GRANDE STREET - SALT LAKE CITY,UT 84101 USA ph: 385-269-0203 fax: 801-821-2872 investor@recursion.com http://www.recursion.com

• General Corporate Information    Officers Najat Khan - Chief Executive Officer and Director Christopher Gibson - Chair of the Board Robert Hershberg - Vice-chair Ben Taylor - Chief Financial Officer Blake Borgeson - Director Peer Information Recursion Pharmaceuticals, Inc. (CORR.) Recursion Pharmaceuticals, Inc. (RSPI) Recursion Pharmaceuticals, Inc. (CGXP) Recursion Pharmaceuticals, Inc. (BGEN) Recursion Pharmaceuticals, Inc. (GTBP) Recursion Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75629V104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 529.91 Most Recent Split Date: (:1) Beta: 1.05 Market Capitalization: $1,595.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 18.83% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.56 Price/Cash Flow: - Price / Sales: 24.02 EPS Growth vs. Year Ago Period: 56.00% vs. Previous Quarter: -4.76% Sales Growth vs. Year Ago Period: -56.11% vs. Previous Quarter: -81.79% ROE 03/31/26 - -54.33 12/31/25 - -63.98 09/30/25 - -72.74 ROA 03/31/26 - -40.60 12/31/25 - -47.05 09/30/25 - -52.46 Current Ratio 03/31/26 - 5.47 12/31/25 - 5.50 09/30/25 - 4.60 Quick Ratio 03/31/26 - 5.47 12/31/25 - 5.50 09/30/25 - 4.60 Operating Margin 03/31/26 - -842.95 12/31/25 - -863.37 09/30/25 - -1,637.81 Net Margin 03/31/26 - -842.95 12/31/25 - -863.37 09/30/25 - -1,637.81 Pre-Tax Margin 03/31/26 - -849.85 12/31/25 - -863.53 09/30/25 - -1,638.15 Book Value 03/31/26 - 1.93 12/31/25 - 2.14 09/30/25 - 2.13 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.01 12/31/25 - 0.01 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.70 12/31/25 - 0.84 09/30/25 - 1.12

Powered by Zacks Investment Research ©